Typhoid Vi polysaccharide vaccine (Sanofi Pasteur)

伤寒Vi多糖疫苗（赛诺菲巴斯德）

Report date: 2026/03/31 20:00:21

Base Information

Drug NameTyphoid Vi polysaccharide vaccine (Sanofi Pasteur)
Drug Alias NameVi capsular polysaccharide vaccine (Sanofi Pasteur)Salmonella typhi capsular polysaccharide vaccineTyphim Vi
ClassificationVaccines > Biological material > Bacterial vaccineVaccines > Development/production technology > Inactivated vaccine > Split vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsStress Disorders, Post-TraumaticDepressive Disorder, MajorImmunologic Deficiency Syndromes +[13] 
Global Approved IndicationsTyphoid Fever
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/03/27
Country/TerritoryCzechiaBelgiumUnited States +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesQueen Mary University Of LondonSanofi KkUniversity Of Virginia
Inactive CompaniesUniversity Of California San FranciscoGlaxosmithkline PlcSanofi Pasteur +[7] 
Active IndicationsImmunologic Deficiency SyndromesCardiovascular DiseasesTyphoid Fever
Inactive IndicationsStress Disorders, Post-TraumaticDepressive Disorder, MajorAsthma +[10] 

Other Information

ATC CodeJ07AP03
Related LinksWikipedia